These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 15468602)

  • 1. Technology evaluation: TroVax, Oxford BioMedica.
    Reinis M
    Curr Opin Mol Ther; 2004 Aug; 6(4):436-42. PubMed ID: 15468602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cross-trial analysis of immunologic and clinical data resulting from phase I and II trials of MVA-5T4 (TroVax) in colorectal, renal, and prostate cancer patients.
    Harrop R; Shingler W; Kelleher M; de Belin J; Treasure P
    J Immunother; 2010; 33(9):999-1005. PubMed ID: 20948436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a phase I/II trial.
    Harrop R; Connolly N; Redchenko I; Valle J; Saunders M; Ryan MG; Myers KA; Drury N; Kingsman SM; Hawkins RE; Carroll MW
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3416-24. PubMed ID: 16740766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 5T4-modified vaccinia Ankara: progress in tumor-associated antigen-based immunotherapy.
    Amato RJ
    Expert Opin Biol Ther; 2010 Feb; 10(2):281-7. PubMed ID: 20088718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Technology evaluation: ALVAC-CEA/B7.1, Aventis Pasteur/Therion.
    Ertl HC
    Curr Opin Mol Ther; 2002 Dec; 4(6):601-5. PubMed ID: 12596363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Technology evaluation: Onyvax-105, Onyvax.
    Blumenthal RD
    Curr Opin Mol Ther; 2003 Dec; 5(6):668-72. PubMed ID: 14755894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TroVax(®) vaccine therapy for renal cell carcinoma.
    Zhang RT; Bines SD; Ruby C; Kaufman HL
    Immunotherapy; 2012 Jan; 4(1):27-42. PubMed ID: 22149999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Technology evaluation: HSPPC-96, antigenics.
    Minev BR
    Curr Opin Mol Ther; 2003 Dec; 5(6):680-7. PubMed ID: 14755896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Technology evaluation: Onyvax-P, Onyvax.
    Doehn C; Böhmer T; Jocham D
    Curr Opin Mol Ther; 2005 Oct; 7(5):511-9. PubMed ID: 16248287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccination of prostate cancer patients with modified vaccinia ankara delivering the tumor antigen 5T4 (TroVax): a phase 2 trial.
    Amato RJ; Drury N; Naylor S; Jac J; Saxena S; Cao A; Hernandez-McClain J; Harrop R
    J Immunother; 2008; 31(6):577-85. PubMed ID: 18528296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Technology evaluation: PROSTVAC, Therion.
    Doehn C; Jocham D
    Curr Opin Mol Ther; 2002 Oct; 4(5):528-34. PubMed ID: 12435056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of pre-treatment markers predictive of treatment benefit for the therapeutic cancer vaccine MVA-5T4 (TroVax).
    Harrop R; Treasure P; de Belin J; Kelleher M; Bolton G; Naylor S; Shingler WH
    Cancer Immunol Immunother; 2012 Dec; 61(12):2283-94. PubMed ID: 22692758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug evaluation: Therion's rV-PSA-TRICOM + rF-PSA-TRICOM prime-boost prostate cancer vaccine.
    Doehn C; Kausch I; Böhmer T; Sommerauer M; Jocham D
    Curr Opin Mol Ther; 2007 Apr; 9(2):183-9. PubMed ID: 17458173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of MVA-5T4 as a novel immunotherapeutic vaccine in colorectal, renal and prostate cancer.
    Amato RJ; Stepankiw M
    Future Oncol; 2012 Mar; 8(3):231-7. PubMed ID: 22409460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccination of renal cell cancer patients with modified vaccinia ankara delivering tumor antigen 5T4 (TroVax) administered with interleukin 2: a phase II trial.
    Amato RJ; Shingler W; Naylor S; Jac J; Willis J; Saxena S; Hernandez-McClain J; Harrop R
    Clin Cancer Res; 2008 Nov; 14(22):7504-10. PubMed ID: 19010868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Technology evaluation: Rexin-G, Epeius Biotechnologies.
    Morse M
    Curr Opin Mol Ther; 2005 Apr; 7(2):164-9. PubMed ID: 15844625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Objective responses in patients with malignant melanoma or renal cell cancer in early clinical studies do not predict regulatory approval.
    Goffin J; Baral S; Tu D; Nomikos D; Seymour L
    Clin Cancer Res; 2005 Aug; 11(16):5928-34. PubMed ID: 16115935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccination with Theratope (STn-KLH) as treatment for breast cancer.
    Holmberg LA; Sandmaier BM
    Expert Rev Vaccines; 2004 Dec; 3(6):655-63. PubMed ID: 15606349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cell fusion technology vaccine tested in kidney cancer clinical trial.
    Expert Rev Anticancer Ther; 2002 Dec; 2(6):620. PubMed ID: 12503204
    [No Abstract]   [Full Text] [Related]  

  • 20. Phase II oncology trials: let's be positive.
    Ratain MJ
    Clin Cancer Res; 2005 Aug; 11(16):5661-2. PubMed ID: 16115898
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.